NCT07217977
An Investigational Study Examining the Efficacy of QbMobile in Treatment Monitoring in Individuals With ADHD
Enrolling by Invitation
Not specifiedAges 6–60ObservationalQbtech AB
~175 participants
Updated 2026-05-06 on ClinicalTrials.gov
What's tested:observational study
At a glance
Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in QbMobile Total Score from Baseline at Visit 3 and Visit 4
Measured over Baseline, Visit 3 (Week 2), and Visit 4 (Week 4)
Conditions
Where it's being run
7 sites across 5 statesFlorida3
Alabama1
California1
North Carolina1
Texas1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Provide written informed consent (including parent/legal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile;
Aged \> 6 years and \< 60 years old;
Referred for an ADHD assessment or has a diagnosis of ADHD but not currently receiving any type of stimulant or nonstimulant medication treatment;
Meets DSM-5 or ICD-11 criteria for a primary diagnosis of ADHD (combined, inattentive, or hyperactivity/impulsive presentation) per sites standard clinical care evaluation;
Qbtech Rating Scale total score of \>24 at Visit 1;
Have adequate sensory and physical ability to complete QbMobile;
Possess or has access to an iPhone model that supports QbMobile.
Exclusion
Intellectual disability designated by IQ\<75);
Has used psychostimulant medication within 7 days prior to Visit 1;
A concurrent medical diagnosis that could significantly affect test performance (brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g., vascular dementia, Alzheimer disease, etc);
Other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain);
Substance use (e.g., alcohol, drugs) that may affect performance on the day of the test.
What this trial measures
- Change in QbMobile Total Score from Baseline at Visit 3 and Visit 4Baseline, Visit 3 (Week 2), and Visit 4 (Week 4)
Change in the QbMobile Total Score from baseline (Visit 2) will be assessed at Visit 3 and Visit 4 to evaluate treatment related responses over time. The QbMobile produces a Total Score number ranging from 0 to 100, where 0 indicates a low likelihood of exhibiting ADHD symptoms and 100 indicates a high likelihood of exhibiting ADHD symptoms. This score is automatically generated in a standard report immediately upon completion of QbMobile.